THE TREND
(Boursier.com) — The CAC40 lined up a fourth session in the red, down 0.41% to 6,660 points at the close, despite China confirming a general easing of its “zero Covid” policy, according to the authorities. local sanitary facilities. According to these new rules, “asymptomatic infected people and mild cases who can be isolated at home will generally be isolated”. This is a radical change: for almost three years, any positive case had to be taken to a quarantine center. Information already anticipated in recent sessions by stock market indices
On the monetary policy side, on the other hand, hesitation remains in order… even if the vast majority of investors expect a tightening of 50 basis points from the Fed and not 75, despite recent economic indicators better than planned in the United States, which caused some trouble on the stock market. The balance also tilts 50 basis points on the side of the ECB at the monetary meeting on December 15, following the slight lull in inflationary pressures in the euro zone, which would bring the main key rate down to 2.5 %.
In the meantime, the euro is camped at 1.05/$. Oil remains heckled at $78 per Brent.
RISING VALUES
Biocorp soared by 33% to more than 20 euros on the Parisian market. The company specializing in the development and manufacture of medical devices and injectable drug delivery systems has received good news from the United States as it has obtained 510(K) clearance from the FDA for marketing in the country of Mallya. The Mallya medical device is a smart sensor that attaches directly to insulin injection pens, transforming them into connected devices. Mallya thus becomes the first system approved in the United States capable of automatically connecting different types of insulin and GLP-1, initially with a version of Mallya compatible with the Solostar injector pens from the Sanofi laboratory.
Leading the CAC40, Sanofi wins 6% to 90.60 euros, driven by a major legal victory in the United States. Several thousand complaints filed in federal justice against the pharmaceutical groups GSK, Pfizer, Boehringer Ingelheim and the French giant establishing a link between Zantac, a drug against gastric acidity, and cancer were dismissed on Tuesday by a Florida judge. Robin Rosenberg, District Judge of West Palm Beach, has indeed considered that the complaints were not supported by solid scientific arguments.
Teleperformance takes back 3%. The subsidiary Teleperformance Colombia has just received from Bureau Veritas the independent certification on the use and inclusion of the international standard ISO 26000 in the field of social responsibility within its operations in Colombia.
Ekinops : +3% with quadient, TFF, Ekinops, SQLI
Ubisoft : +2.5% with Nakon
Elis gained 2.5%, the highest since early September. It must be said that the group specializing in cleaning and hygiene benefits from strong support since JP Morgan has raised its recommendation on the issue to ‘overweight’ while maintaining its target at 16.5 euros.
Latecoere : +2% with country house (+1.5%), Haulotte, ID Logistics
Company of the Alps : +1% followed by Tikehau, Savencia, Lagardere,Seb
FALLING VALUES
Euroapi drops by 15%. In the context of a temporary suspension of certain production activities at its Budapest site, Euroapi has updated its financial forecasts for 2022. This temporary and targeted suspension of production will affect Euroapi’s activity and financial performance. As a result, the group anticipates consolidated revenue of around €980 million and a Core EBITDA margin of between 12% and 13% in 2022, due to lost sales, related provisions and costs. of remediation. The group estimates that the production of prostaglandins could remain stopped for a few weeks.
Genomics : -7% with dare, CGG (-5.5%), AB Science (-5%)
The negative series continues for Kering which still loses 4.5% and aligns a fifth consecutive session in the red. Despite the good news from China, the title of the luxury group is the victim of a rating from UBS which has degraded to ‘neutral’ its recommendation on the value with an adjusted objective of 575 to 572 euros.
Showroomprivé : -4.5% with Faurecia, Valneva
Vallourec : -3.5% with Orpea
Alstom down 3.1%. Morgan Stanley downgraded the group to ‘line weighted’.
Ramsay : -2.5% with Thales, S30 and Stedim
Airbus loses 2.2%, while the aeronautics giant finally abandoned its target for commercial aircraft deliveries in 2022. Citing a complex operating environment after reporting 68 deliveries in November, the group now considers that its goal of reaching “approximately 700” commercial aircraft deliveries in 2022 is “out of reach”. However, the final figure “should not be significantly below target” and financial targets were maintained. Airbus thus still expects to reach around 5.5 billion euros in adjusted EBIT in 2022 and 4.5 billion euros in Free Cash-Flow. The group has also indicated that it wants to adjust the production rate of A320 family aircraft for 2023 and 2024 to 65 per month. Airbus still expects to be able to produce 75 per month by the middle of the decade.